IRS
Price
$14.13
Change
-$0.01 (-0.07%)
Updated
Jun 27 closing price
Capitalization
859.33M
71 days until earnings call
IVA
Price
$3.05
Change
-$0.12 (-3.79%)
Updated
Jun 27 closing price
Capitalization
429.8M
87 days until earnings call
Interact to see
Advertisement

IRS vs IVA

Header iconIRS vs IVA Comparison
Open Charts IRS vs IVABanner chart's image
IRSA Inversiones Y Representaciones S.A
Price$14.13
Change-$0.01 (-0.07%)
Volume$119.77K
Capitalization859.33M
Inventiva SA
Price$3.05
Change-$0.12 (-3.79%)
Volume$7.53K
Capitalization429.8M
IRS vs IVA Comparison Chart in %
Loading...
IRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IRS vs. IVA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRS is a Buy and IVA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (IRS: $14.13 vs. IVA: $3.05)
Brand notoriety: IRS and IVA are both not notable
IRS represents the Real Estate Development, while IVA is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: IRS: 86% vs. IVA: 36%
Market capitalization -- IRS: $859.33M vs. IVA: $429.8M
IRS [@Real Estate Development] is valued at $859.33M. IVA’s [@Biotechnology] market capitalization is $429.8M. The market cap for tickers in the [@Real Estate Development] industry ranges from $165.37B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Real Estate Development] industry is $5.44B. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IRS’s FA Score shows that 2 FA rating(s) are green whileIVA’s FA Score has 0 green FA rating(s).

  • IRS’s FA Score: 2 green, 3 red.
  • IVA’s FA Score: 0 green, 5 red.
According to our system of comparison, IRS is a better buy in the long-term than IVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IRS’s TA Score shows that 3 TA indicator(s) are bullish.

  • IRS’s TA Score: 3 bullish, 6 bearish.

Price Growth

IRS (@Real Estate Development) experienced а +1.80% price change this week, while IVA (@Biotechnology) price change was -7.29% for the same time period.

The average weekly price growth across all stocks in the @Real Estate Development industry was +2.74%. For the same industry, the average monthly price growth was +4.86%, and the average quarterly price growth was +3.25%.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

IRS is expected to report earnings on Sep 09, 2025.

IVA is expected to report earnings on Sep 25, 2025.

Industries' Descriptions

@Real Estate Development (+2.74% weekly)

Activities range from the renovation and re-lease of existing buildings to the purchase of raw land and the sale of developed land or parcels to others. Demand for land development business is driven by GDP growth, employment rates, interest rates, and access to/cost of capital. For individual companies in this industry, proper cost estimation and successful bidding play critical roles in their profitability. Large companies could potentially have greater access to capital, while smaller companies can specialize in a specific geographic area or market niche. CBRE Group, VICI Properties Inc and Brookfield Property Partners L.P. are some of the large companies in this industry.

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IRS($859M) has a higher market cap than IVA($430M). IVA YTD gains are higher at: 42.523 vs. IRS (-5.358).
IRSIVAIRS / IVA
Capitalization859M430M200%
EBITDA240BN/A-
Gain YTD-5.35842.523-13%
P/E Ratio3.67N/A-
Revenue94.5BN/A-
Total Cash118BN/A-
Total Debt326BN/A-
FUNDAMENTALS RATINGS
IRS: Fundamental Ratings
IRS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
PROFIT vs RISK RATING
1..100
19
SMR RATING
1..100
49
PRICE GROWTH RATING
1..100
51
P/E GROWTH RATING
1..100
62
SEASONALITY SCORE
1..100
44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IRS
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 13 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
IRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMWX13.350.06
+0.45%
Goldman Sachs Emerging Mkt Eq ex. Chn R6
PRRAX28.300.09
+0.32%
Principal Real Estate Securities A
MXLSX37.390.12
+0.32%
Empower Small Cap Value Inv
SMVFX11.060.03
+0.27%
Virtus Ceredex Mid-Cap Value Equity C
IVSOX22.370.05
+0.22%
Voya SmallCap Opportunities Port I

IVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IVA has been loosely correlated with DRUG. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then DRUG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
-3.65%
DRUG - IVA
39%
Loosely correlated
-6.09%
TVGN - IVA
35%
Loosely correlated
+5.08%
IVF - IVA
30%
Poorly correlated
-11.75%
OCGN - IVA
24%
Poorly correlated
-4.46%
IMMP - IVA
23%
Poorly correlated
+0.61%
More